PRELIMINARY PROGRAMME

Non-replacement therapies in the hemophilias: Update

09.00

Fitusiran
Steve Pipe (USA)

09.30

APC Serpin
James Huntington (UK)

10.00

Anti-TFPI
Alan Mast (USA)

10.30

Thrombotic microangiopathies using emicizumab: a role for complement?
TBA

11.00

Break

Gene Therapy

11.30

New strategies for a better and safer gene transfer: less immunogenic
TBA

12.00

Liver toxicity in gene therapy
TBA

12.30

Industry Lecture
TBA

13.00

Lunch

14.00

Industry Symposium
TBA

Other Novel drugs

15.00

Caplacizumab: results of phase II/phase III studies
TBA

15.30

Break

Immunotolerance induction in hemophilia (Part I)

16.00

How to maintain tolerance in hemophilia A
Sebastien Lacroix-Desmazes (France)

16.30

How to induce Treg responses in experimental hemophilia A
TBA

17.00

Is it important to induce immune tolerance in the era of non-replacement therapies?
Elena Santagostino (Italy)

17.30

Nanoparticles and immunetolerance induction
David Scott (USA)

18.00

Walking Poster Session